Literature DB >> 11556767

Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.

M R McGinnis1, N Nordoff, R K Li, L Pasarell, D W Warnock.   

Abstract

One hundred clinical isolates of Sporothrix schenckii were tested against voriconazole, itraconazole and amphotericin B using a modification of the NCCLS M27-A in vitro yeast susceptibility testing procedure. NCCLS M38-P for moulds was not used because yeast forms may have been present when the test isolates were incubated at 35 +/- 1 degrees C. The minimum inhibitory concentration (MIC) values were: voriconazole 0.5-8 (geometric mean titer 6.50) microg ml(-1) ; itraconazole 0.03-8 (geometric mean titer 1.56) microg ml(-1); and amphotericin B 0.25-2 (geometric mean titer 1.23) microg ml(-1). The minimum fungicidal concentration (MFC) values were: voriconazole 2-8 (geometric mean titer 7.67) microg ml(-1); itraconazole 0.125-8 (geometric mean titer 7.41) microg ml(-1); and amphotericin B 0.125-2 (geometric mean titer 1.53) microg ml(-1). Based upon MIC values, sensitivity to amphotericin B is strain-dependent. S. schenckii is more sensitive to itraconazole than voriconazole based upon a comparison of MIC geometric means, even though the MIC ranges were essentially the same.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556767     DOI: 10.1080/mmy.39.4.369.371

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  15 in total

1.  In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia Dos Santos Lazéra; Bodo Wanke; Armando de Oliveira Schubach; Rodrigo de Almeida Paes; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 2.  Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature.

Authors:  Simone Appenzeller; Tiago Nardi Amaral; Eliane Maria Ingrid Amstalden; Manoel Barros Bertolo; João Francisco Marques Neto; Adil Muhib Samara; Sandra Regina M Fernandes
Journal:  Clin Rheumatol       Date:  2005-12-07       Impact factor: 2.980

3.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

4.  Molecular identification of Sporothrix clinical isolates in China.

Authors:  Ting-ting Liu; Ke Zhang; Xun Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

5.  In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.

Authors:  Eidi Alvarado-Ramírez; Josep M Torres-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

Review 6.  Sporothrix schenckii and Sporotrichosis.

Authors:  Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; Armando Oliveira Schubach
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

7.  Human sporotrichosis: recommendations from the Brazilian Society of Dermatology for the clinical, diagnostic and therapeutic management.

Authors:  Rosane Orofino-Costa; Dayvison Francis Saraiva Freitas; Andréa Reis Bernardes-Engemann; Anderson Messias Rodrigues; Carolina Talhari; Claudia Elise Ferraz; John Verrinder Veasey; Leonardo Quintella; Maria Silvia Laborne Alves de Sousa; Rodrigo Vettorato; Rodrigo de Almeida-Paes; Priscila Marques de Macedo
Journal:  An Bras Dermatol       Date:  2022-09-22       Impact factor: 2.113

8.  In vitro antifungal susceptibilities of five species of sporothrix.

Authors:  Rita Marimon; Carolina Serena; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

9.  Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest.

Authors:  Rita Marimon; Josep Cano; Josepa Gené; Deanna A Sutton; Masako Kawasaki; Josep Guarro
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

10.  Update on the optimal use of voriconazole for invasive fungal infections.

Authors:  Asma Lat; George R Thompson
Journal:  Infect Drug Resist       Date:  2011-02-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.